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Androgen deprivation therapy (ADT) is standard for advanced
prostate cancer and is now increasingly used as adjunct ther-
apy in high-risk or locally advanced disease and for the treat-
ment of recurring disease based on rising prostate-specific
antigen levels. Testosterone stimulates bone formation di-
rectly by stimulating the osteoblast proliferation, inhibiting
the apoptosis of both osteoblasts and osteoclasts, and indi-
rectly by being a precursor of oestrogen which is also involved
in inhibiting osteoclastic function (bone resorption). The ef-
fects of testosterone on preserving bone health are lost in
the hypogonadal state induced by ADT [1]. The impact of
ADTon bone loss and osteoporosis is well established through
multiple studies. In one of these studies, non-metastatic
prostate cancer cases were followed for 10 years; none of
the patients on ADT had normal bone mass density (BMD)
at the end of the study, and the prevalence of osteoporosis
(T score < 2.5) was approximately 50% by 4 years and 80%
by 10 years in men on ADT [2].
Bone metastases will occur in over 90% of men with lethal
castration-resistant prostate cancer (CRPC). Due to the com-
bined effect of bone fragility due to ADT and the presence of
bone metastases, almost all patients will experience some
form of morbidity related to bone metastases prior to suc-
cumbing from the disease. Complications go beyond pain
and include pathological fracture, the need for palliative radi-
ation or surgery, and spinal cord compression. These events
impair quality of life and place a significant burden on
health-care resources.2. Management options
2.1. Life style modification and supplementation
Regular exercise, smoking cessation, lowering alcohol and
caffeine intake, as well as oral vitamin D (800 IU daily) and
calcium (500–1500 mg daily) supplementation are helpful in
attenuating ADT-related bone loss, but they are insufficient
to prevent or treat ADT-induced bone loss [3].2.2. Bone targeted therapy (anti-resorptive agents)
Bisphosphonates are the first and most widely used of the
anti-resorptive agents. Due to their structural similarity to
pyrophosphate, a normal component of bone matrix, they
are integrated in the bone matrix by binding to hydroxyapa-
tite crystals, resulting in inhibition of osteoclast-mediated
bone resorption. Non-nitrogen-containing bisphosphonates
are metabolized by osteoclasts to cytotoxic compounds, while
nitrogen-containing bisphosphonates exert their effects on
osteoclasts and tumour cells by inhibiting a key enzyme in
the mevalonate pathway and by inducting osteoclast apopto-
sis. Nitrogen-containing bisphosphonates (e.g., pamidronate,
zoledronic acid) are more potent than non-nitrogen-contain-
ing bisphosphonates (e.g., clodronate). Zoledronic acid is un-
ique in that it contains two nitrogen groups, and it has been
shown to be 40–850-fold more potent than other bisphospho-
nates [4].
In the setting of non-metastatic prostate cancer, bisphos-
phonates have consistently been found to reduce BMD loss
associated with ADT in multiple randomized controlled trials,
but none have had sufficient power or duration to demon-
strate a reduction in fractures [5].
Zoledronic acid is the only bisphosphonate and the first
osteoclast-targeted agent that has shown a protective effect
against skeletal-related events (SRE) in patients with meta-
static castration-resistant prostate cancer. The phase 3 study
showed a 48% reduction in the mean annual incidence of SRE
(P = 0.005), 5 months prolongation in the median time to first
SRE (P = 0.009) and 36% reduction in the ongoing risk of SREs
at 24 months [6,7].
Bisphosphonate-induced nephrotoxicity is a major con-
cern, especially with intravenous bisphosphonates. Renal
function monitoring and dose adjustment according to creat-
inine clearance are crucial to prevent significant deterioration
in renal function. Other side effects include self-limiting flu-
like symptoms occurring with the first infusions, hypocalca-
emia and osteonecrosis of the jaw (ONJ) [8].
The zoledronic acid bone metastases prevention study
recently reported their results. The Zometa European Study
[ZEUS] reported that there was no difference in the
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prostate cancer. Of note, the incidence of new metastases
was very low at approximately 13% [9].
Denosumab is a receptor activator of nuclear factor kappa B
(RANK), a member of the tumour necrosis factor (TNF) recep-
tor superfamily expressed by osteoclast precursors, and its li-
gand (RANKL) plays an essential role in regulating the
osteoclast life cycle at different levels. Binding of the RANKL,
secreted by osteoblasts and bone-marrow stromal cells, to its
receptor RANK leads to differentiation, activation, and sur-
vival of osteoclasts which induce bone resorption [10].
Denosumab is a fully human monoclonal antibody that
specifically targets RANKL, thus effectively inhibiting osteo-
clastic function and bone resorption, In a randomised pla-
cebo-controlled study in patients with non-metastatic
prostate cancer receiving ADT, denosumab (60 mg subcutane-
ously every 6 months) was associated with significant
improvements in BMD at the lumbar spine (6.7%), the total
hip (4.8%) and distal one third of the radius (5.5%). Denosu-
mab was also the first agent to show a reduction in the inci-
dence of new vertebral fractures (1.5% versus 3.9%; P = 0.006)
in patients on ADT [11].
In the setting of metastatic CRPC, denosumab (120 mg sub-
cutaneously every 4 weeks) compared to zoledronic acid
(4 mg intravenously every 4 weeks) significantly improved
the time to first SRE (20.7 versus 17.1 months; P < 0.001 for
non-inferiority; P = 0.008 for superiority). Overall survival
and progression-free survival were similar for both drugs.
Hypocalcaemia was more common with denosumab (13%)
than with zoledronic acid (6%) (P < 0.0001) and a non-signifi-
cant trend towards higher osteonecrosis of the jaw was seen
with denosumab (2.3% versus 1.3%; P = 0.09) [12]. Calcium and
vitamin D supplementation and monitoring of calcium levels
while on therapy are essential to reduce the risk of
hypocalcemia.
In another placebo-controlled trial in non-metastatic
CRPC, denosumab (120 q monthly) significantly increased
the bone-metastasis-free survival in patients with non-meta-
static CRPC by a median of 4.2 months (29.5 versus 25.2
months; HR, 0.85; 95%CI, 0.73–0.98; P = 0.028) [17]. Although
hypocalcaemia was much lower in the setting of non-meta-
static CRPC, the risk of ONJ was higher given the longer expo-
sure time to denosumab [13].
2.3. Osteonecrosis of the jaw (ONJ)
Osteonecrosis of the jaw is defined as exposed necrotic bone
in the maxillofacial region that persists for more than 8
weeks. The incidence of ONJ in patients with CRPC receiving
denosumab was similar to that in patients receiving zoled-
ronic acid [12]. Although the aetiology is unclear, duration
of therapy, poor dental hygiene, invasive dental surgery or
ill-fitting dentures, concomitant corticosteroid use, radiother-
apy and chemotherapy are identified risk factors. A conserva-
tive approach to the management of ONJ is recommended
and includes oral rinses, antibiotics, pain control and mini-
mal surface bony debridement to reduce sharp or rough bone
surfaces. Biopsies are not recommended unless metastasis to
the jaw is suspected. Good oral hygiene, baseline dental eval-
uation for high-risk individuals and avoidance of invasivedental surgery during therapy reduce the risk of ONJ [14–16].
Most of the cases that were reported had had a tooth extrac-
tion or some other form of trauma that may have contributed
to the development of ONJ. Most cases were treated conserva-
tively, and less than 10% required bone resection. It is esti-
mated that the risk is approximately 1–2% per year of
exposure to bone-targeted therapies such as zoledronic acid
and denosumab. Although bone-targeted therapy is benefi-
cial, one must consider the risk of ONJ after 2 years of therapy
when deciding whether to continue therapy.2.4. Radiopharmaceuticals – (radium-223)
In a recently completed phase III study of patients with met-
astatic CRPC, patients were randomized on a 2:1 basis to
either radium-223 (an alpha-emitting bone seeker) or placebo.
To be eligible for the study patients had to have bone metas-
tases and to have progressed after chemotherapy or were not
eligible to receive chemotherapy. Patients received either ra-
dium-223 or placebo every 4 weeks intravenously. Overall sur-
vival (OS) was the primary endpoint. Median survival was 14
months for the treated patients as opposed to 11.2 months
for those who received a placebo, conferring approximately
a 30% improvement in OS (HR = 0.699, P = 0.0022). The up-
dated analysis involving 921 patients confirmed the radium-
223 survival benefit (median, 14.9 months vs. 11.3 months;
hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P < 0.001). The study
also showed a 5-month delay in time to skeletal-related
events. This agent has recently been approved by the FDA
and is the first bone-targeted agent to demonstrate a survival
advantage.3. Conclusion
Patients with metastatic prostate cancer are at high risk for
skeletal complications, including debilitating bone pain often
requiring palliative radiation therapy, pathological fractures,
and spinal cord compression. These complications impair
quality of life and place a significant burden on health-care
resources. They are due to the combined effects of bone
metastases and ADT-related bone loss. The use of bone-tar-
geted therapy (denosumab and zoledronic acid) has been
shown to significantly delay and reduce the risk of these skel-
etal complications. Studies have also suggested that introduc-
tion of these therapies prior to PAIN or SREs may further
improve efficacy. Denosumab (60 mg every 6 months) has re-
cently been approved for prevention of bone loss related to
ADT. Most recently the radiopharmaceutical, radium-223,
was shown to delay skeletal complications and also to im-
prove overall survival in patients ineligible for or having failed
chemotherapy. The combination of early bone-targeted ther-
apy followed by radium-223 later in the disease continuum
appears to lead to further improvements in the management
of bone metastases in CRPC.Conflict of interest statement
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